Prognose

Das durchschnittliche Kursziel der Analysten beträgt +12,80€(+553,06%). Der Median liegt bei +12,80€(+553,06%).

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

MDxHealth SA (MDXH) Q1 2025 Earnings Call Transcript
MDxHealth SA (NASDAQ:MDXH ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Corporate Participants John Fraunces - LifeSci Advisors, IR Michael McGarrity - Chief Executive Officer Ron Kalfus - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair Mark Massaro - BTIG Dan Brennan - UBS Jason Bednar - Piper Sandler Thomas Vranken - KBC Securities Nelson Cox - Lake Street Capital Markets Operator Good day and welcome to the MDxHealth First Quarter 2025 Earnings Conference Call. [Operator Instructions] I would now like to turn the conference over to Mr.» Mehr auf seekingalpha.com
MDxHealth SA (MDXH) Reports Q1 Loss, Tops Revenue Estimates
MDxHealth SA (MDXH) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.31 per share a year ago.» Mehr auf zacks.com
MDxHealth Reports Q1-2025 Results
Year-over-year Q1 revenues increase by 22% to $24.3 million 71% year-over-year improvement in adjusted EBITDA in first quarter Conference call with Q&A today at 4:30 PM ET / 22:30 CET» Mehr auf globenewswire.com

Im letzten Quartal hatte MDXHEALTH S.A. ADR einen Umsatz von 22,45 Mio€ und ein Nettoeinkommen von −8,51 Mio€